Ryan Townsend, MD
Pulmonary Disease · Marlton, NJNPI 1194188375
Payments from drug & device makers
Across 126 payments — averaging $21.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$667
- AstraZeneca$488
- Inspire Medical Systems, Inc.$176
- Regeneron Healthcare Solutions, Inc.$156
- Sanofi$140
- Philips North America LLC$136
- plus $1K from 21 others
What the payments were for
- Food & beverage$2,66996%
- Education$1004%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 33 | $667 |
| AstraZeneca | 21 | $488 |
| Inspire Medical Systems, Inc. | 4 | $176 |
| Regeneron Healthcare Solutions, Inc. | 8 | $156 |
| Sanofi | 7 | $140 |
| Philips North America LLC | 6 | $136 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $128 |
| Grifols USA, LLC | 5 | $109 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Actelion Pharmaceuticals US, Inc. | 6 | $98 |
| Verona Pharma, Inc. | 5 | $95 |
| Jazz Pharmaceuticals Inc. | 3 | $55 |
| Mylan Specialty L.p. | 3 | $50 |
| Baxter Healthcare | 1 | $47 |
| ANI Pharmaceuticals, Inc. | 2 | $43 |
| Genentech USA, Inc. | 2 | $39 |
| Boehringer Ingelheim | 2 | $35 |
| Harmony Biosciences LLC | 2 | $35 |
| Novartis | 1 | $32 |
| Vapotherm Inc | 1 | $27 |
| Resmed Corp | 1 | $18 |
| Insmed, Inc. | 1 | $18 |
| Bayer | 1 | $17 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| Azurity Pharmaceuticals, Inc. | 1 | $16 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $15 |
| Gilead | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,769 in reported general payments places this provider in the 50th percentile of 472 pulmonary disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 91 | $64,311 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 52 | $48,672 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 17 | $12,400 |
| Breo ElliptaFluticasone/Vilanterol | 25 | $10,789 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 34 | $8,039 |
| Spiriva RespimatTiotropium Bromide | 15 | $7,928 |
| Incruse ElliptaUmeclidinium Bromide | 15 | $7,878 |
| DuleraMometasone/Formoterol | 13 | $5,758 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 11 | $5,116 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 21 | $4,919 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 111 | $3,912 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $3,723 |
| Wixela InhubFluticasone Propion/Salmeterol | 12 | $1,127 |
| Montelukast Sodium | 58 | $414 |
| Fluticasone Propionate | 32 | $390 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $667 | $79,738109 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $488 | $68,034106 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $35 | $13,04426 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 472 pulmonary disease providers in New Jersey.
Other pulmonary disease in Marlton
- Allen SalmMarlton$87K
- Heather GianniniMarlton$22K
- Thomas NugentMarlton$20K
- Reynold PanettieriNew Brunswick$2.5M
- Vinay SikandToms River$1.8M
- Stanley FielMorristown$1.3M
- Joseph HoffmanPark Ridge$1.1M
- Robert SussmanSummit$645K
- Ronaldo GoHackensack$563K
- Deborah GossHackensack$558K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.